The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)

The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) are a group of primary vasculitides that affect predominantly small- to medium-sized blood vessels. AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with p...

Full description

Bibliographic Details
Main Authors:	Thomas Daikeler, Andreas D. Kistler, Pierre-Yves Martin, Bruno Vogt, Uyen Huynh-Do
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2015-01-01
Series:	Swiss Medical Weekly
Subjects:	rituximab first-line treatment relapsed/refractory disease cyclophosphamide glucocorticoids methotrexate
Online Access:	https://www.smw.ch/index.php/smw/article/view/1980

Similar Items

Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study
by: Renée Ysermans, et al.
Published: (2023-01-01)

Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly
by: Roberta Fenoglio, et al.
Published: (2020-10-01)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
by: Frank B. Cortazar, et al.
Published: (2018-03-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Combination of rituximab and low-dose glucocorticoids for idiopathic refractory nephrotic syndrome with MCD/FSGS: a single-center prospective cohort study
by: Aikeda Yimamuyushan, et al.
Published: (2024-12-01)

A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy
by: Yi Wang, et al.
Published: (2024-12-01)

A retrospective cohort study of biosimilar rituximab therapy in pemphigus: experience from a tertiary care hospital in North India
by: Sabha Mushtaq, et al.
Published: (2024-11-01)

Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis
by: Masoud Etemadifar, et al.
Published: (2020-02-01)

Rituximab Therapy for Severe Cutaneous Leukocytoclastic Angiitis Refractory to Corticosteroids, Cellcept and Cyclophosphamide
by: Kamel El-Reshaid, et al.
Published: (2013-04-01)

Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report
by: O. Psenak, et al.
Published: (2021-08-01)

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience
by: Ping Chen, et al.
Published: (2023-02-01)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
by: Sasanka Handunnetti, et al.
Published: (2021-05-01)

Comparison of rituximab, cyclophosphamide, and tacrolimus as first steroid-sparing agents for complicated relapsing/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life
by: Li Wang, et al.
Published: (2022-01-01)

Rituximab resistance in ITP and beyond
by: Zhengrui Xiao, et al.
Published: (2023-07-01)

Rituximab Twice Weekly for Refractory Thrombotic Thrombocytopenic Purpura in a Critically Ill Patient with Acute Respiratory Distress Syndrome
by: Bahjat Azrieh, et al.
Published: (2020-02-01)

Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab
by: Sudulagunta, Sreenivasa Rao, et al.
Published: (2016-10-01)

A comparative study to evaluate the efficacy and cost of rituximab versus dexamethasone cyclophosphamide pulse in patients of pemphigus vulgaris
by: Sudip Das, et al.
Published: (2021-01-01)

Oral cyclophosphamide treatment for clinical periocular inflammation of unknown origin
by: Arash Maleki, et al.
Published: (2024-10-01)

Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions
by: Lemiale V, et al.
Published: (2021-06-01)

Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study
by: Irene Dogliotti, et al.
Published: (2024-07-01)

Comparative retrospective evaluation of efficacy of rituximab therapy with dexamethasone cyclophosphamide pulse therapy in patients of pemphigus vulgaris at a tertiary care hospital
by: Preema Sinha, et al.
Published: (2020-01-01)

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma
by: Robin Noel, et al.
Published: (2023-12-01)

Progressive outer retinal necrosis after rituximab and cyclophosphamide therapy
by: Mohit Dogra, et al.
Published: (2018-01-01)

An acute infection due to hepatitis E in the context of a patient with rituximab and methotrexate therapy
by: Francisco Josué Cordero Pérez, et al.
Published: (2024-03-01)

Exploration of rituximab treatment strategies for membranous nephropathy adapted to the Chinese healthcare environment
by: Xiaolong Wang, et al.
Published: (2025-01-01)

B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients
by: Jens Thiel, et al.
Published: (2017-05-01)

Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of Clinicians
by: David Massicotte-Azarniouch, et al.
Published: (2024-08-01)

International guidelines for the management ofANCA-associated systemic vasculitides
by: T. V. Beketova
Published: (2019-03-01)

The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature
by: S. Barsotti, et al.
Published: (2018-07-01)

Successful use of combined corticosteroids and rituximab in a patient with refractory cutaneous polyarteritis nodosa
by: Ibrahim A. Al-Homood, et al.
Published: (2017-01-01)

Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis
by: Luying Lu, et al.
Published: (2024-12-01)

Rituximab in Refractory Myasthenia Gravis – Challenges and Lessons Learnt
by: Karthika A Valaparambil, et al.
Published: (2024-12-01)

Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
by: Cheng Xue, et al.
Published: (2023-09-01)

Intravenous Rituximab in Severe Refractory Primary Focal Segmental Glomerulosclerosis
by: Wee Leng Gan, et al.
Published: (2018-10-01)

Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients
by: Konstantinos Thomas, et al.
Published: (2021-03-01)

Effectiveness of using rituximab in membranous nephropathy: a clinical case
by: I.M. Zavalna, et al.
Published: (2024-09-01)

Comparison of rituximab vs. cyclophosphamide in rheumatoid arthritis-associated interstitial lung disease and its correlation with spirometry
by: Mohammed Abdullah Saleem, et al.
Published: (2024-12-01)

Severe Wegener's granulomatosis successfully treated with rituximab
by: E N Semenkova, et al.
Published: (2010-06-01)

Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi
by: Sei Adachi, et al.
Published: (2022-02-01)